NCT03915951 2026-03-24
An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
Pfizer
Phase 2 Completed
Pfizer
Pfizer
Pfizer
University Health Network, Toronto
Abramson Cancer Center at Penn Medicine
Pfizer
Novartis